Literature DB >> 3729353

Comparative pharmacokinetics of azlocillin and piperacillin in normal adults.

P A Colaizzi, R E Polk, W J Poynor, A C Raffalovich, E A Cefali, L A Beightol.   

Abstract

The single-dose pharmacokinetics of azlocillin and piperacillin were compared by using a randomized, crossover design. The concentrations of azlocillin in serum were consistently higher than those of piperacillin throughout an 8-h study. The area under the time-concentration curve of azlocillin was significantly greater than that of piperacillin, and the total body clearance of azlocillin was significantly lower than that of piperacillin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729353      PMCID: PMC284187          DOI: 10.1128/AAC.29.5.938

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  High-performance liquid chromatographic determination of piperacillin in plasma.

Authors:  A M Brisson; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

2.  Dose dependence of piperacillin pharmacokinetics.

Authors:  T Bergan; J D Williams
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

Review 3.  Review of the pharmacokinetics and dose dependency of azlocillin in normal subjects and patients with renal insufficiency.

Authors:  T Bergan
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

4.  Antibiotics against Pseudomonas.

Authors:  A P Gillett
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

5.  Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

6.  Pharmacokinetics of piperacillin in subjects with various degrees of renal function.

Authors:  P G Welling; W A Craig; R W Bundtzen; F W Kwok; A U Gerber; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

7.  Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.

Authors:  A Leroy; G Humbert; M Godin; J P Fillastre
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Pharmacokinetics of azlocillin in healthy subjects.

Authors:  A Leroy; G Humbert; J P Fillastre
Journal:  Scand J Infect Dis Suppl       Date:  1981

Review 9.  Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

10.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  4 in total

1.  Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers.

Authors:  R D Lander; R P Henderson; D R Pyszczynski
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 2.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

3.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

4.  Applications of minimal physiologically-based pharmacokinetic models.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-23       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.